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A B S T R A C T
Objective: Female breast cancer patients carrying a BRCA1/2-mutation have an increased risk of second
primary breast and ovarian tumors. Little is known about the psychological impact and treatment
consequences of rapid genetic counseling and testing offered between breast cancer diagnosis and
surgery.
Methods: Female breast cancer patients, who had received rapid genetic counseling (and optional
testing) (RGC(T)) at The Netherlands Cancer Institute between 2004 and 2008, received a questionnaire
in 2009.
Results: BRCA-mutations were found in 10 of the 26 participants. Six mutation-carriers (60%) had an
immediate bilateral mastectomy, compared with 25% of those without a mutation. Five patients (19%)
reported having frequent worries about cancer recurrence; none indicated that such worries impaired
daily functioning. Six patients had clinically relevant levels of breast cancer-speciﬁc distress at the time
of assessment.
Conclusion: These results suggest that RGC(T) in high-risk breast cancer patients may inﬂuence surgical
treatment, without causing long-term psychosocial distress in the majority.
Practice implications: These results are important, since rapid genetic counseling and testing are
expected to be offered to newly diagnosed breast cancer patients with increasing frequency in order to
inform these women and their surgeons about the possible familial/hereditary nature of their disease
before deciding on treatment.
 2012 Elsevier Ireland Ltd. 
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Breast cancer affects approximately 12% of all women in
Western countries [1,2]. Between 5 and 10% of breast cancers is
associated with a hereditary predisposition, characterized by
young age at diagnosis and/or multiple relatives with breast,
ovarian and/or prostate cancer [3,4]. Approximately 15% of women
whose breast cancer is associated with a hereditary predisposition
have a BRCA1 or BRCA2 gene mutation [5]. Such patients have a
risk of up to 60% of developing contralateral breast cancer and a
risk of up to 60% of developing ovarian cancer, depending on the
age of ﬁrst breast cancer diagnosis and the affected gene [6–13].* Corresponding author at: The Netherlands Cancer Institute – Antoni van
Leeuwenhoek Hospital, Division of Psychosocial Research and Epidemiology &
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Open access under the Elsevier OA license.Because of these increased risks, breast cancer patients carrying a
BRCA1/2 mutation may opt for additional preventive surgery
[14,15]. A bilateral mastectomy (BLM) or (delayed) contralateral
prophylactic mastectomy (CPM) substantially reduces the risk of
contralateral breast cancer, although studies on survival have
yielded mixed results [16–20]. A risk-reducing salpingo-oopho-
rectomy (RRSO) reduces the risk of ovarian cancer in BRCA1/2
carriers, also after a prior diagnosis of breast cancer [14]. Even
when no pathogenic mutation is found (i.e., an inconclusive DNA
test result), breast cancer patients with a strong family history of
breast and/or ovarian cancer may still have an increased risk of a
second primary tumor, and may choose to undergo additional
preventive surgery [6,15,21].
Genetic counseling and testing are usually offered to high-risk
breast cancer patients after their primary treatment [22–24]. As a
consequence, additional preventive surgery is often performed
after primary treatment. Currently, breast cancer patients with an
increased risk of having hereditary breast cancer can technically be
referred for genetic counseling and possibly DNA testing after their
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DNA testing can be done quickly (with a time to report test results
within a few weeks) in order to provide additional information
relevant to making treatment decisions [21,24]. However, this
rapid genetic counseling (and optional testing) (RGC(T)) takes
place only infrequently [23].
It has been hypothesized that women diagnosed with breast
cancer who undergo RGCT and are found to be a BRCA1/2 mutation
carrier will opt more often for a unilateral or bilateral mastectomy
(and not breast conserving surgery), and will avoid radiotherapy in
order to keep open the option to undergo breast reconstruction
[25,26]. The studies performed, to date, lend support to this
hypothesis [15,27–31]. Between 50% and 100% of breast cancer
patients found to carry a BRCA1/2 mutation chose to undergo a BLM
or a delayed CPM. Also, a substantial percentage of high-risk
patients who tested negative for a BRCA1/2 mutation opted for BLM
[15,27]. These percentages are much higher than those found in the
general breast cancer population, where approximately 20% opts
for a CPM [32]. However, in these sometimes very small studies,
referral, timing of genetic counseling and testing and type of
counselor were not always similar. High-risk patients had
sometimes initiated RGCT themselves, had already been counseled
before diagnosis, had not always been counseled before surgical
treatment or had sometimes been counseled by their treating
surgeon.
There is little information about how many and which women
would want to address the possible genetic component of their
breast cancer and to take preventive measures at a time when
their primary concern is survival. In a small study of genetic
counseling in newly diagnosed breast cancer patients by
Vadaparampil et al., all women said their genetic counseling
was timely and relevant, although only 3 of the 9 women had
genetic counseling prior to surgical treatment [33]. In another
study by Vadaparampil, 16 of 26 high-risk breast cancer patients
receiving a referral letter by their surgeon pursued genetic
counseling. However, of the women who did not have genetic
counseling, many said this would be overwhelming at a time
when being diagnosed and treated for cancer [34]. Also, concerns
have been expressed that RGC(T) may trigger additional
psychological distress, above and beyond that caused by the
breast cancer diagnosis itself, although genetic counseling and
testing offered after surgical treatment does not increase
psychological distress [21,22,35,36]. To our knowledge, there
are no data on the psychological status of women more than a year
after they received RGC(T). Furthermore, it is unknown how many
breast cancer patients who receive RGC(T) also receive psychoso-
cial counseling. It is also unknown which topics patients who
receive RGC(T) consider important to discuss with a psychosocial
worker. For example, it is not clear whether patients want to
discuss issues concerning genetic counseling, in general, or more
speciﬁcally issues on prophylactic treatment options.
Since it is expected that RGC(T) will be offered with increasing
frequency to newly diagnosed breast cancer patients, it is
important to better understand its inﬂuence on treatment
decision-making and its impact on psychological well-being
[21]. Toward this end, we have carried out an observational study
of high-risk breast cancer patients who have been referred for
RGC(T) as part of usual care in The Netherlands Cancer Institute –
Antoni van Leeuwenhoek Hospital in Amsterdam, The
Netherlands. To our knowledge, this is the ﬁrst study covering
both treatment consequences and psychological issues in patients
who received RGC(T) in a usual care setting. The aim of this study
was to better understand why women choose to undergo RGC(T),
how it impacts on choice of treatment, psychological experiences
at the time of RGC(T), current levels of distress, and whether
women are satisﬁed with the procedures.2. Methods
2.1. Sample
Patients were eligible if they were female, 18 years of age or
older at the time of breast cancer diagnosis, capable of
understanding the Dutch language sufﬁciently to complete the
questionnaire and had received RGC(T). Referral for genetic
counseling and testing was based on the guideline of the Dutch
Association of Comprehensive Cancer Centers [37,38].
2.2. Procedure
This study employed a cross-sectional retrospective design. All
women who received RGC(T) between January, 2004 and Novem-
ber, 2008 at the Family Cancer Clinic of The Netherlands Cancer
Institute – Antoni van Leeuwenhoek Hospital and were still alive
were invited to complete a mailed questionnaire. Respondents
were asked to provide written informed consent. RGC(T) was
deﬁned as a ﬁrst appointment with the clinical geneticist between
breast cancer diagnosis and ﬁrst surgery, and within 28 days of the
referral by the surgeon to the family cancer clinic. We used this
time period between referral and ﬁrst appointment, since this
indicated an accelerated process of genetic counseling and testing,
i.e., the normal waiting time at that time was approximately 40
days. Opting for DNA testing, and receiving DNA test results before
ﬁrst surgery, were not necessary for inclusion. At the Family Cancer
Clinic, all diagnosed BRCA1/2 mutation carriers are offered and
recommended to take advantage of professional psychosocial
counseling.
2.3. Study measures
Sociodemographic and clinical data: The patients’ age, education,
marital status, number and age of children, work status, and family
history were obtained via a self-report questionnaire [39]. Clinical
data, including age at breast cancer diagnosis, treatment history,
timing of genetic counseling and testing in relation to breast cancer
diagnosis, and genetic test results, were obtained both via the
questionnaire and the medical records.
The following psychosocial measures were assessed in the self-
report questionnaire (see Table 1): reasons for undergoing RGC(T),
inﬂuence of RGC(T) on treatment decisions, perceived psychologi-
cal impact of RGC(T), quality and quantity of psychosocial care
received, cancer-speciﬁc distress, breast cancer-speciﬁc distress,
and satisfaction with RGC(T).
2.4. Data analyses
Student’s t-tests for independent samples or analysis of
variance (ANOVA) were used to test for group differences for
interval-level data, and chi-square tests were used to compare
differences between two groups for categorical data. Correlations
were calculated using Pearson’s R. All statistical analyses were
performed using SPSS version 17.0. A 2-sided p-value of 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Response
Thirty-one women received RGC(T) during the period under
investigation. Of these 31 women, 1 had died and 26 completed the
questionnaire (response = 87%). The mean age of the respondents
did not signiﬁcantly differ from that of the non-respondents (mean
age = 38.4 versus 35.5, p = 0.54).
Table 1
Psychosocial measures.
Outcome variables Number of items (scoring) References Description of questions
Reasons to opt
for RGCT
1 Based on a questionnaire
developed by Bleiker
et al. [49]
Participants were asked to choose a maximum of 5
reasons from a list of 15 possible reasons to opt for RGCT.
Inﬂuence of RGCT
on treatment
2 Self developed ‘‘How much inﬂuence did genetic counseling and testing
have on the choice of breast cancer treatment?’’; ‘‘Was
the (ﬁrst) breast cancer surgery postponed to wait for
the results of genetic counseling and testing?’’
Psychological
impact of RGCT
1 Self developed ‘‘Did RGCT cause additional distress on top of the
distress already caused by the breast cancer diagnosis?’’
Quality and quantity
of received
psychosocial care
13 Self developed Questions concerning whether the participant had
psychosocial counseling, by whom, how many
appointments, when during the RGCT process, whether
they would have liked more appointments, how useful
psychosocial counseling was, which topics were
important and whether psychosocial counseling should
be offered to every patient opting for RGCT.
Cancer-speciﬁc
distress
8 (4-point scale: never
to almost always)
Adapted cancer worry scale,
Crohnbach’s alpha 0.88
(based on Lerman and
Watson) [42,50,51]
The 6 original items address frequency of cancer-related
worries, their impact on mood and their impact in daily
functioning. The 2 added items address worries about
cancer in family members and possible future surgery.
Breast-cancer-
speciﬁc distress
15-item scale organized into two
subscales: ‘‘intrusion’’ and
‘‘avoidance’’ (4-point scale:
0, never; 1, seldom; 3,
sometimes; 5, often)
Separate scale rating of distress:
0–8 low; 9–19 moderate; 20 high
9 is considered as clinically
relevant
Total cutoff score for clinically
relevant distress 26
Impact of events scale (IES),
Crohnbach’s alpha >0.80 [35,40]
Event = breast cancer diagnosis
Satisfaction
with RGCT
4 (3 questions with a 5-point
scale: very satisﬁed to very
unsatisﬁed; 1 question
‘yes/no/don’t know’)
Questions concerning satisfaction with the fact the
participant had RGCT, the timing of RGCT, the time it
took to report results and whether the participant would
recommend RGCT to other breast cancer patients.
Satisfaction with
Decision-making
5 of the original 6 items
(5-point scale: don’t agree
at all to very much agree)
0.86 for the 6-item scale Satisfaction with Decision Scale [52]
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The sociodemographic characteristics of the participants are
described in Table 2. Time between ﬁrst appointment with a
clinical geneticist and questionnaire completion was between 7
months and 63 months, with a mean of 29.2 months (SD 14.5).Table 2
Characteristics of participants.
Participants (n = 26)
Age
Mean age, range/SD (years) 38.4 (range 20–60, SD 9.1)
Marital/partner status
Single 2
Partner 24
Education
Low 0
Medium 6
High 20
Children
Yes 16
No 10
Diagnosis
Unilateral breast cancer 24
Synchronous bilateral breast cancer 2
DNA test results
BRCA1 mutation 4
BRCA2 mutation 6
Inconclusive 15
Non-carrier of familial mutation 1The mean number of counseling sessions the patients had was
3.5 (SD 2.7), with a median of 3 and a range of 1–15. All 26 patients
had had DNA testing, although not all patients opted for DNA
testing at the time of the ﬁrst genetic counseling session. The time
between the ﬁrst genetic counseling session and DNA test results
ranged from 6 to 767 days (25 months), with a median of 40 days.
For 18 patients, test results were known prior to surgery. There
were no statistically signiﬁcant differences observed between the
18 patients who knew their DNA test results before ﬁrst surgery
and the 8 women who received their test results after ﬁrst surgery
on the following variables: age, being a carrier or not, having
children or not, total number of counseling sessions and treatment
with neo-adjuvant chemotherapy or not. There also was no
statistically signiﬁcant difference in total levels of cancer-speciﬁc
distress and breast-cancer speciﬁc distress.
Ten of the 26 patients were BRCA1/2 gene mutation carriers (4
BRCA1 and 6 BRCA2). One of the two patients with synchronous
bilateral breast cancer carried a BRCA2 mutation; the other 9
mutations were found in patients with unilateral breast cancer.
One patient with unilateral breast cancer was a non-carrier of the
familial mutation. The other 15 patients had an inconclusive test
result.
3.3. Reasons for undergoing RGC(T)
The most important reasons for undergoing RGC(T) were ‘‘to
obtain certainty about the risk of developing breast cancer again’’
(73%), ‘‘to be able to take preventive actions for the unaffected
breast’’ (69%) and ‘‘to be able to choose surgical treatment of the
Table 3
Reasons for receiving rapid genetic counseling and testing (n = 26).
Reasons to opt for RGCT, in order of importance n %
To obtain certainty about the risk of getting breast cancer again 19 73
To be able to take preventive actions for the unaffected breast 18 69
To be able to choose surgical treatment of the affected breast 13 50
To obtain certainty about the risk of ovarian cancer 12 46
To estimate the risk of cancer for my children 12 46
To be able to take preventive actions for the ovaries 9 35
To understand why I got cancer 8 31
Referred by a physician 8 31
Family planning 4 15
Worried about cancer recurrence 4 15
To be able to choose adjuvant therapy 3 12
To be able to decide on hormonal therapy 1 4
General planning for the future 1 4
To help science 1 4
Requested by a family member 0 0
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mentioned by more than one-third of the women were ‘‘to obtain
certainty about ovarian cancer risk’’ (46%), ‘‘to estimate the risk of
cancer for children’’ (46%) and ‘‘to be able to take preventive
actions for the ovaries’’ (35%).
3.4. Impact on treatment
Of the 9 patients with unilateral breast cancer who carried a
BRCA mutation, 5 had a bilateral mastectomy as ﬁrst surgery (56%),
compared with 3 of 15 women with unilateral breast cancer26  
participants
Synchronous  
bilateral  
breast  
cancer 
2 
DNA test result  
before  
first surgery 
1 
DNA test result  
after  
first surgery 
1 
BRCA  
mutation 
carrier 
1 
Inconclusive  
test  
result 
1 
BLM 
1 
 BLM 
1 
DNA test result  
before  
first surgery 
17 
BRCA  
mutation  
carrier 
7 
o
BCT 
1 
 ULM
2 
 BLM
4 
 BCT
5 
 
RRSO
3 
Secondary
ULM 
1 
Secondary 
CPM 
1 
Fig. 1. DNA test results and choice of ﬁrst surgery (BLM: bilateral mastectomy, ULM: un
oophorectomy).without a BRCA mutation (20%) (p = 0.07). Both of the women with
bilateral breast cancer underwent a bilateral mastectomy. In total,
5 women (4 carriers and 1 non-carrier) had a risk-reducing
salpingo-oophorectomy (RRSO).
Of the 18 patients who knew their test results before surgery, 17
had unilateral breast cancer. Of those 17, 6 had a BLM as ﬁrst
surgery. Of the 7 women with unilateral breast cancer who
received their test results after their ﬁrst surgery, 2 had a BLM as
ﬁrst surgery (p = 0.75). Not all women in the last group provided a
motivation for the fact they did not wait for their test results, but
one mentioned that she ‘‘wanted to have her surgery as soon as
possible’’ and two mentioned that ‘‘choice of the type of surgery
was already clear’’. One of these two women had a BLM, the other
had a unilateral mastectomy (Fig. 1).
3.5. Psychosocial impact of RGC(T)
3.5.1. Perceived distress at time of RGC(T)
Fourteen women (54%) indicated that RGC(T) had caused
additional distress, above and beyond that caused by the diagnosis
of breast cancer. Five women (19%) reported that RGCT had
lowered their distress levels, and 7 (27%) indicated that it had had
no effect on distress.
3.5.2. Use of psychosocial services
Nine patients (35%) indicated having received psychosocial
counseling by a social worker (n = 6) or psychologist (n = 3) at
variable moments in the RGCT process; seven reported this as
(very) useful. Mutation carriers more often indicated havingUnilateral 
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ilateral mastectomy, BCT: breast conserving therapy, RRSO: risk reducing salpingo-
Table 4
Subjects for discussion with a psychosocial worker.
Subjects N
Considers this
as a (very)
important
issue
Would like to
discuss this
issue with
psychosocial
worker
Risk of cancer in children or
other relatives (n = 13)
10 7
Recurrence risk (n = 14) 10 6
Cope with cancer (n = 13) 8 5
Consequences of (prophylactic)
surgery (n = 14)
8 5
Body image (n = 14) 8 4
Choice of medical treatment (n = 14) 7 4
Relationship problems (n = 14) 6 5
Complications of medical
treatments (n = 14)
6 4
Mood disturbance (n = 14) 6 3
Genetic counseling and testing (n = 14) 5 5
Communication with doctor (n = 14) 5 3
Fatigue (n = 14) 5 3
Questions on life and death (n = 14) 5 3
Consequences for work/study/
school/social activities (n = 14)
5 3
Informing children/relatives (n = 13) 5 3
Physical complaints (n = 13) 5 1
Sexual functioning (n = 14) 4 4
Fear of regular screening (n = 13) 4 3
Former psychological
problems (n = 13)
4 2
Coping with loss of relatives
(n = 15, n = 13)
4 1
Desire to have children (n = 14) 3 2
Feelings of guilt toward children
or other relatives (n = 13)
0 0
Table 5
Cancer worries (n = 26).
Items of the cancer worry scale,
referring to the 7 days before
completion of the questionnaire
Never/
sometimes
N (%)
Often/
always
N (%)
1 How often have you thought
about your chances of getting
cancer (again)?
21 (81) 5 (19)
2 Have these thoughts
affected your mood?
23 (89) 3 (12)
3 Have these thoughts
interfered with your
ability to do daily activities?
26 (100) 0 (0)
4 How concerned are you
about the possibility of
getting cancer one day?
21 (81) 5 (19)
5 How often do you worry
about developing cancer?
22 (85) 4 (15)
6 How much of a problem
is this worry?
24 (92) 2 (7)
7 How often do you worry
about the chance of family
members developing cancer?
24 (92) 2 (7)
8 How concerned are you about
the possibility that you will
ever need surgery (again)?
23 (89) 3 (12)
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pathogenic mutation (3/16, p = 0.03). Important topics, according
to the 15 patients who completed this question, were ‘‘recurrence
risk’’, ‘‘cancer risk in children and other relatives’’, ‘‘coping with
cancer’’, ‘‘consequences of (prophylactic) surgery’’ and ‘‘body
image’’ (Table 4).
3.5.3. Current levels of cancer-speciﬁc distress (CWS)
Five of 26 women (19%) indicated being often or always worried
about the possibility of developing cancer again. However, none of
the women indicated that these worries interfered with their
ability to carry out normal daily activities (see Table 5). A trend was
observed for more cancer worries in BRCA1/2 mutation carriers
compared to those without a pathogenic mutation (p = 0.06). No
signiﬁcant association was observed between cancer worries and
age, level of education, or having children.
3.5.4. Current levels of breast cancer-speciﬁc distress (IES)
Thirteen of 26 women (50%) scored in the moderate to high
range on the intrusion subscale, and 7 women (27%) on the
avoidance subscale of the IES. On each subscale, one (different)
woman scored in the high range which indicated pathological
levels of breast cancer-speciﬁc distress. However, 6 women (23%)
had a total IES score of 26, indicating clinically relevant levels of
current distress (on average, 2.5 years post-diagnosis) [35,40].
At the subscale level, education, having children and BRCA1/2
mutation status were not related to intrusion-scores. However,
mutation carriers had signiﬁcantly higher scores on the avoidance
subscale than patients without a pathogenic mutation (p = 0.04).
Similarly, the mean total IES score was signiﬁcantly higher for the
mutation carriers than for those without a pathogenic mutation
(mean = 22.8 versus 11.4, p = 0.02). Older women reported
signiﬁcantly less breast cancer-speciﬁc distress as compared toyounger women (p = 0.02). Time since RGC(T) (categorical: less
than 12 months, 12–24 months and >24 months) was not
associated with current levels of breast cancer-speciﬁc distress. In
patients with unilateral breast cancer, type of breast surgery and
having undergone a prophylactic oophorectomy were not associ-
ated signiﬁcantly with current levels of breast cancer-speciﬁc
distress.
3.5.5. Satisfaction with RGC(T)
Almost all women (25 of 26) were (very) satisﬁed with the fact
that they had received RGCT, 24 were (very) satisﬁed with the
timing of RGCT, and 23 were (very) satisﬁed with the speed with
which DNA test results were made available. The mean score on
the ﬁve item satisfaction with decision scale was high (22.3, SD 2.2,
on a scale ranging from 5 to 25), indicating high levels of
satisfaction with the choice of primary breast cancer treatment.
One woman indicated that she had not been adequately informed
about the issues important to her decision on surgery. Nineteen
patients (73%) would recommend RGC(T) to other high-risk breast
cancer patients. The other six patients did not know if they would
recommend RGC(T). The large majority (88%) of the respondents
believed that the best timing for genetic counseling and testing is
between breast cancer diagnosis and surgery.
4. Discussion and conclusion
4.1. Discussion
In this study we investigated why newly diagnosed breast
cancer patients undergo RGC(T), their treatment decisions, their
psychosocial health and satisfaction with RGC(T). To our knowl-
edge, as an observational study, this is the ﬁrst such investigation
of RGC(T) in an usual care setting, i.e., referral by a physician for
genetic counseling and possibly DNA testing provided by a clinical
geneticist, between diagnosis and surgery. Stolier et al. reported
their experience with genetic counseling and testing soon after
breast cancer diagnosis. However, in their study not all patients
underwent counseling prior to their initial breast surgery, and
patients were counseled primarily by their surgeon only [29,30]. In
other studies, patients received RGCT in experimental settings
where patients had already had genetic counseling before breast
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receive RGCT [15,28].
We found that the primary reasons for patients to undergo
RGC(T) were to obtain certainty about the risk of developing breast
cancer again and being able to choose (preventive) surgical
treatment in case of an increased cancer risk. The frequency with
which these reasons for undergoing pre-surgical RGC(T) were
given was much higher than that reported by Vadaparampil et al.
[33], and by Schlich-Bakker et al. in a study of genetic counseling
and testing during adjuvant radiotherapy (i.e., after primary
surgery) [41]. Strikingly, 46% of the women in our study also
reported ‘‘obtaining certainty about ovarian cancer risk’’ as a
motive for undergoing RGC(T). Notably, we suspect that this may
reﬂect current (i.e., retrospective) reasoning on the part of the
respondents, rather than motives at the time of undergoing
RGC(T). That is, we believe that few women would have known
about the association between breast and ovarian cancer risk at the
time they underwent RGC(T), but rather learned of this association
via the genetic counseling.
Although choice of surgical treatment did not differ signiﬁcant-
ly between women with and without a BRCA1/2 mutation, this
may have been due to lack of statistical power. We did observe a
clear trend toward more bilateral mastectomies as ﬁrst surgery in
unilateral breast cancer patients with a pathogenic gene mutation
(56%) versus those without (20%). The percentage of mutation
carriers with unilateral breast cancer that opted for a BLM is quite
comparable to that reported in previous studies, where between
half and 88% of mutation carriers underwent BLM or delayed CPM
[15,27–29]. Also, a similar percentage of patients with unilateral
breast cancer without a BRCA1/2 mutation opted for BLM (20% in
our study versus 5–24% in previous studies) [15,27,29].
With regard to the short-term psychosocial experiences,
approximately half of the women in our study reported that
RGC(T) had caused additional distress on top of that already
experienced as a result of the breast cancer diagnosis. This added
distress was not, however, found to be associated with the DNA
test result.
Approximately one-third of the women in our study reported
having received psychosocial counseling. It is not clear how this
compares to breast cancer patients receiving genetic counseling
and testing after primary treatment. Data have been published on
use of psychosocial counseling by patients receiving genetic
counseling (and testing) for Familial Adenomatous Polyposis and
Von Hippel Lindau syndrome. In these types of hereditary cancer,
17 and 28%, respectively, reported having received professional
psychosocial support [42,43]. This is less frequently than among
patients in our study. We suspect that genetic counselors may be
more attentive to possible psychosocial problems in patients
receiving RGC(T) than in patients receiving genetic counseling and
testing after treatment. We also found that mutation carriers
underwent psychosocial counseling more often than women
without a pathogenic mutation. This is in accordance with the
policy to offer newly diagnosed mutation carriers professional
psychosocial counseling.
Women in our study who had received psychosocial counseling
indicated that it was important for them to discuss general, cancer-
related topics (e.g., how to cope with cancer), topics related to
hereditary cancer and genetic counseling, in general (e.g., cancer
risk in children and other relatives), as well as topics related to
possible effects of RGC(T) (e.g., recurrence risk, consequences of
(prophylactic) surgery and body image). This suggests that, for
these women, undergoing RGC(T) was not the only reason for
seeking psychosocial counseling.
Approximately one-quarter of the women in our study reported
clinically relevant levels of breast cancer-speciﬁc distress at the
time of questionnaire completion. At the subscale level, this wassomewhat higher (50% on the intrusion scale and 27% on the
avoidance scale). This is comparable to the patients treated with
radiotherapy for early stage breast cancer studied by Bleiker et al.,
who found that on average 21 months after surgery 47% (intrusion
scale) and 33% (avoidance scale) respectively reported clinically
relevant levels of breast cancer-speciﬁc distress [44]. In our study,
younger women and those who had a positive DNA test result were
more likely to report clinically relevant levels of distress. However,
given the cross-sectional nature of the study, and the absence of a
control or comparison group of women who did not undergo
RGC(T), it is not possible to attribute current distress levels to
genetic susceptibility or to the counseling/testing process. For this
purpose, ideally data should be generated in the context of a
prospective, randomized trial.
Over 90% of the women in our study were satisﬁed with RGC(T).
About three-quarters would recommend RGC(T) and notably no
one would advise against it. This is relevant if we want to offer
rapid testing more frequently in the near future.
Our sample exhibited some remarkable characteristics. First, a
relatively large number of BRCA1/2 mutations were found (38%).
This suggests that those breast cancer patients who were referred for
RGC(T) form a very selective group of women at very high risk of
carrying a BRCA mutation; higher than the average risk of patients
receiving genetic counseling and testing, in general. Second, the
majority of participants were highly educated. It has been described
that breast cancer patients who undergo genetic counseling are
relatively highly educated [45–47], although this probably also
reﬂects the relatively high educational level of patients treated in
this particular hospital; one of two specialized cancer treatment
hospitals in The Netherlands. This suggests that some caution be
used in generalizing results to other hospital settings.
Several limitations of the study should be noted. First, as
already noted, the study had a cross-sectional and retrospective
character. Second, we only were able to trace women who had
actually undergone RGC(T) in the period of interest. There may
well have been women who were referred to RGC(T) but did not
pursue it. Third, the sample size was small, limiting the statistical
power and the ability to perform subgroup analyses. Finally, the
absence of a control group of breast cancer patients with a possible
hereditary disposition who did not undergo RGC(T) did not allow
us to evaluate rigorously the impact of RGC(T) on treatment
decisions and psychological well-being. To overcome these
limitations, we and others are currently conducting a large,
multicenter, prospective, randomized controlled trial [48];
Schwartz et al. NCT00262899.
4.2. Conclusion
In conclusion, the results of our study suggest that the offer of
RGC(T) to high-risk breast cancer patients may inﬂuence surgical
treatment, without causing signiﬁcant short- or long-term distress.
4.3. Practice implications
These results are important, since rapid genetic counseling and
testing are expected to be offered to newly diagnosed breast cancer
patients with increasing frequency in order to inform these women
and their surgeons about the possible familial/hereditary nature of
their disease prior to deciding on primary surgery and adjuvant
treatment [24]. Before this study, little was known about the effect
of rapid genetic counseling and testing on choice of treatment or its
psychological burden. This is the ﬁrst investigation of RGC(T) in a
usual care setting. Our data may therefore be of great importance
to breast cancer surgeons, oncologists and genetic counselors who
consider offering rapid genetic counseling and testing to their
patients.
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